ICB International
Pioneering breakthrough technology enabling new non-invasive diagnostics and therapeutics for CNS diseases like neurodegeneration, cancer, and infections.
Pioneering breakthrough technology enabling new non-invasive diagnostics and therapeutics for CNS diseases like neurodegeneration, cancer, and infections.
ICB International is a biotechnology and healthcare startup that has been pioneering breakthrough technology in the field of non-invasive diagnostics and therapeutics for CNS diseases. Established in 2008, the company's unique blood-brain barrier permeable technology is at the forefront of addressing challenges associated with central nervous system diseases. Utilizing this platform technology, ICBI is working on developing FDA-approved non-invasive diagnostics and treatments for neurodegenerative, cancer, and infectious diseases. The company secured a $895.00K Venture Round investment on 19 April 2013, showcasing investor interest in their innovative approach. With a focus on cutting-edge solutions in the areas of neurodegeneration, cancer, and infections, ICB International stands as a promising player in the biotech and healthcare industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $895.00K | - | 19 Apr 2013 |
No recent news or press coverage available for ICB International.
-logo.){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
